Andrew Cleeland joins atHeart Medical’s Board

atHeart Medical, today announced the appointment of Andrew Cleeland to the company’s Board of Directors.

First Five Patients Successfully Treated

atHeart Medical announced today the successful treatment of the first five patients in its ASCENT ASD U.S. Investigational Device

atHeart Medical has commenced operations

atHeart Medical announced today that it has commenced operations and is initiating its U.S. Investigational Device Exemption (IDE) trial.

Beginning with a purpose

I couldn’t be more enthusiastic about our purpose at atHeart Medical: allowing more future options for patients with atrial septal defects (ASDs) by reducing device footprint.…

July 14, 2021

First Five Patients Successfully Treated with reSeptTM ASD Occluder in U.S. IDE Pivotal Trial

atHeart Medical announced today the successful treatment of the first five patients in its ASCENT ASD U.S. Investigational Device Exemption (IDE) pivotal trial. This study, the company’s first in the US, will evaluate the safety and efficacy of the reSept ASD Occluder.

Read more

April 20, 2021

atHeart Medical has commenced operations and is initiating its U.S. IDE trial.

atHeart Medical announced today that it has commenced operations and is initiating its U.S. Investigational Device Exemption (IDE) trial.

Read more

Sigler M, Söderberg B, Schmitt B, Mellmann A, Bernhard J. Carag bioresorbable septal occluder (CBSO): histopathology of experimental implants. EuroIntervention. 2018 Feb 20;13(14):1655-1661 Read more